Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 30

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 30
---
 million for the second quarter of 2024. The decrease of $17 million was primarily driven by lower cash and cash equivalents and marketable securities in the second quarter of 2025 as a result of the ProfoundBio acquisition, compared to the second quarter of 2024.

#### Foreign Exchange Rate Gain, Net
Foreign exchange rate gain, net was $6 million in the second quarter of 2025 compared to the foreign exchange rate gain, net of $2 million in the second quarter of 2024. The DKK strengthened against the USD in the second quarter of 2025, positively impacting our DKK denominated cash holdings.

Corporate Tax Corporate tax expense for the first six months of 2025 was $136 million compared to $161 million for the first six months of 2024. The decrease in corporate tax expense is primarily the result of Genmab’s lower estimated annual effective tax rate in the first six months of 2025 of 20.3% compared to 28.9% in the first six months of 2024.

Key Developments to Corporate Tax – Second Quarter of 2025

Corporate tax expense for the second quarter of 2025 was $87 million compared to $104 million for the second quarter of 2024. The decrease in corporate tax expense is primarily the result of Genmab’s lower estimated annual effective tax rate.

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 20/44                  
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
Net Profit Net profit for the first six months of 2025 was $531 million compared to $395 million in the first six months of 2024. The increase was driven by the items described above.

#### Liquidity and Capital Resources
|                           |     |   | June 30, 2025 |     |   | December 31, 2024 |
|:--------------------------|:----|:--|--------------:|:----|:--|------------------:|
| Marketable securities     |     | $ |         1,603 |     | $ |             1,574 |
| Cash and cash equivalents |     | $ |         1,296 |     | $ |